{"DataElement":{"publicId":"6961728","version":"1","preferredName":"Bladder Carcinoma Timepoint Disease Response Status","preferredDefinition":"The response indicating the disease response status of the patient with bladder carcinoma at an indicated time point.","longName":"BLD_CRCN_DS_RSP_ST","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"6957920","version":"1","preferredName":"Bladder Carcinoma Timepoint Disease Response","preferredDefinition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas._A specific point in the time continuum, including those established relative to an event._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"3135356v1.0:6957918v1.0","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"3135356","version":"1","preferredName":"Bladder Carcinoma","preferredDefinition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","longName":"C4912","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Carcinoma","conceptCode":"C4912","definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC1173C-8ADA-5FB1-E040-BB89AD432078","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6957918","version":"1","preferredName":"Timepoint Disease Response","preferredDefinition":"A specific point in the time continuum, including those established relative to an event.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C68568:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Timepoint","conceptCode":"C68568","definition":"A specific point in the time continuum, including those established relative to an event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F52331-F6E2-7B26-E053-F662850A5A8B","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F52331-F6F3-7B26-E053-F662850A5A8B","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"HARTLEYG","dateModified":"2019-10-03","changeDescription":"Curated to support Protocol GU_TRIOBLADDER1_02352","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6959189","version":"1","preferredName":"Bladder Carcinoma Disease Response Status","preferredDefinition":"A condition or state at a particular time.","longName":"BLD_CRCN_DS_RSP_ST","context":"DCI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Residual low grade tumor in upper tract and endoscopic management possible","valueDescription":"Possible Endoscopic Procedure Residual Low Grade Upper Urinary System Carcinoma","ValueMeaning":{"publicId":"6959193","version":"1","preferredName":"Possible Endoscopic Procedure Residual Low Grade Upper Urinary System Carcinoma","longName":"6959193","preferredDefinition":"Capable of happening or occurring.: A diagnostic or therapeutic procedure in which an endoscope is inserted in a tubular organ to examine the structural architecture and/or remove abnormal tissues.: Remaining or left behind.: Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.: Higher in place or position; the topmost one of two.: The organs involved in the creation and excretion of urine.: A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Possible","conceptCode":"C82490","definition":"Capable of happening or occurring.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Endoscopic Procedure","conceptCode":"C16546","definition":"A diagnostic or therapeutic procedure in which an endoscope is inserted in a tubular organ to examine the structural architecture and/or remove abnormal tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Low Grade","conceptCode":"C14161","definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Upper","conceptCode":"C25355","definition":"Higher in place or position; the topmost one of two.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Urinary System","conceptCode":"C12413","definition":"The organs involved in the creation and excretion of urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F59405-3772-2AC8-E053-F662850A6CDF","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-378B-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Residual muscle invasive bladder cancer","valueDescription":"Residual Muscle Invasion Bladder Carcinoma","ValueMeaning":{"publicId":"6959191","version":"1","preferredName":"Residual Muscle Invasion Bladder Carcinoma","longName":"6959191","preferredDefinition":"Remaining or left behind.: A morphologic finding indicating the presence of a malignant cellular infiltrate invading muscle in a tissue sample.: A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Muscle Invasion","conceptCode":"C150571","definition":"A morphologic finding indicating the presence of a malignant cellular infiltrate invading muscle in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bladder Carcinoma","conceptCode":"C4912","definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F59405-371C-2AC8-E053-F662850A6CDF","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-3735-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Residual low grade tumor in upper tract and endoscopic management not possible","valueDescription":"Impossible Endoscopic Procedure Residual Low Grade Upper Urinary System Carcinoma","ValueMeaning":{"publicId":"6959192","version":"1","preferredName":"Impossible Endoscopic Procedure Residual Low Grade Upper Urinary System Carcinoma","longName":"6959192","preferredDefinition":"Not able to occur, exist, or be done.: A diagnostic or therapeutic procedure in which an endoscope is inserted in a tubular organ to examine the structural architecture and/or remove abnormal tissues.: Remaining or left behind.: Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.: Higher in place or position; the topmost one of two.: The organs involved in the creation and excretion of urine.: A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Impossible","conceptCode":"C154661","definition":"Not able to occur, exist, or be done.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Endoscopic Procedure","conceptCode":"C16546","definition":"A diagnostic or therapeutic procedure in which an endoscope is inserted in a tubular organ to examine the structural architecture and/or remove abnormal tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Low Grade","conceptCode":"C14161","definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Upper","conceptCode":"C25355","definition":"Higher in place or position; the topmost one of two.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Urinary System","conceptCode":"C12413","definition":"The organs involved in the creation and excretion of urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F59405-3747-2AC8-E053-F662850A6CDF","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-3760-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Residual high grade non-muscle invasive bladder cancer","valueDescription":"Residual High Grade Absence of Muscle Invasion Bladder Carcinoma","ValueMeaning":{"publicId":"6959195","version":"1","preferredName":"Residual High Grade Absence of Muscle Invasion Bladder Carcinoma","longName":"6959195","preferredDefinition":"Remaining or left behind.: Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.: No Value Exists: A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"High Grade","conceptCode":"C14158","definition":"Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Absence of Muscle Invasion","conceptCode":"C61108","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bladder Carcinoma","conceptCode":"C4912","definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F59405-379B-2AC8-E053-F662850A6CDF","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-37B4-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Progression in lymph node","valueDescription":"Lymph Node Disease Progression","ValueMeaning":{"publicId":"6959196","version":"1","preferredName":"Lymph Node Disease Progression","longName":"6959196","preferredDefinition":"A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.: The worsening of a disease over time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymph Node","conceptCode":"C12745","definition":"A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F59405-37D9-2AC8-E053-F662850A6CDF","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-37F2-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Progression in upper tract","valueDescription":"Upper Urinary System Disease Progression","ValueMeaning":{"publicId":"6959197","version":"1","preferredName":"Upper Urinary System Disease Progression","longName":"6959197","preferredDefinition":"Higher in place or position; the topmost one of two.: The organs involved in the creation and excretion of urine.: The worsening of a disease over time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Upper","conceptCode":"C25355","definition":"Higher in place or position; the topmost one of two.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Urinary System","conceptCode":"C12413","definition":"The organs involved in the creation and excretion of urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F59405-3800-2AC8-E053-F662850A6CDF","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-3819-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Progression in bladder","valueDescription":"Bladder Disease Progression","ValueMeaning":{"publicId":"6959198","version":"1","preferredName":"Bladder Disease Progression","longName":"6959198","preferredDefinition":"The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.: The worsening of a disease over time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder","conceptCode":"C12414","definition":"The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F59405-3826-2AC8-E053-F662850A6CDF","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-383F-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Stable disease","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-3849-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Objective response","valueDescription":"Objective Improvement","ValueMeaning":{"publicId":"6959200","version":"1","preferredName":"Objective Improvement","longName":"6959200","preferredDefinition":"An improvement that can be measured by the health care provider (for example, when a tumor shrinks or there are fewer cancer cells in the blood).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Objective Improvement","conceptCode":"C94227","definition":"An improvement that can be measured by the health care provider (for example, when a tumor shrinks or there are fewer cancer cells in the blood).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F59405-3856-2AC8-E053-F662850A6CDF","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-386F-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Complete remission","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F59405-3879-2AC8-E053-F662850A6CDF","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"M1 progression (distant progression)","valueDescription":"M1 Stage Finding","ValueMeaning":{"publicId":"3201565","version":"1","preferredName":"M1 Stage Finding","longName":"3201565","preferredDefinition":"A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M1 TNM Finding","conceptCode":"C48700","definition":"A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E24E347-9EA5-3835-E040-BB89AD4379CD","latestVersionIndicator":"Yes","beginDate":"2011-03-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F5B522-8477-3020-E053-F662850A23AB","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Residual low grade non-muscle invasive bladder cancer","valueDescription":"Residual Low Grade Absence of Muscle Invasion Bladder Carcinoma","ValueMeaning":{"publicId":"6959201","version":"1","preferredName":"Residual Low Grade Absence of Muscle Invasion Bladder Carcinoma","longName":"6959201","preferredDefinition":"Remaining or left behind.: Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.: No Value Exists: A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Low Grade","conceptCode":"C14161","definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Absence of Muscle Invasion","conceptCode":"C61108","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Bladder Carcinoma","conceptCode":"C4912","definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F5AA1E-6EDD-3E00-E053-F662850AE1E9","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93F5AA1E-6EF6-3E00-E053-F662850AE1E9","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"ONEDATA","dateModified":"2019-10-02","deletedIndicator":"No"},{"value":"Progression","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"3284666","version":"1","preferredName":"Progressive Disease","longName":"3284666v1.00","preferredDefinition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9FC7D6-531D-BE97-E040-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"MMADDINENI","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2023.5.17 Alt VM added per ticket request CADSR0002435. ak \r\n2023.3.15 Per LS at COG Protocol defined progressive disease (should have been added as a VM Alt Name for PV 3284666). ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"94A835BF-6E9E-3954-E053-F662850A940A","beginDate":"2019-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-11","modifiedBy":"ONEDATA","dateModified":"2019-10-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F59405-3701-2AC8-E053-F662850A6CDF","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"HARTLEYG","dateModified":"2019-10-11","changeDescription":"Curated to support Protocol GU_TRIOBLADDER_102352","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the treatment respons","type":"Preferred Question Text","description":"What is the treatment response (at this time point)?","url":null,"context":"DCI"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93F51596-CAEE-7B0D-E053-F662850AAD09","latestVersionIndicator":"Yes","beginDate":"2019-10-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-02","modifiedBy":"HARTLEYG","dateModified":"2019-10-03","changeDescription":"Curated to support protocol GU_TRIOBLADDER_102352","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}